Core Insights - The overall pace of the "淘汰赛" (elimination competition) for 惠民保 (Huiminbao) is slowing down, indicating a maturation phase in the market with a stabilization in the number of operational products and a slight increase in market scale [1][2] Group 1: Market Development - As of July 31, 2025, a total of 313 local 惠民保 products have been launched, with 202 currently operational, reflecting a decrease from 211 in the previous year [1] - The market growth rate for 惠民保 products has slowed, with only 9 new products added in the current year, resulting in a growth rate of 2.96% [2] - The market is transitioning from "incremental expansion" to "stock optimization," focusing on high-quality development [2] Group 2: Pricing and Product Structure - The average price of basic 惠民保 products has risen to approximately 95 yuan, up from around 60 yuan in 2021 [3] - A shift from a single pricing model to a differentiated pricing model is occurring, with 141 products currently using a single price and 70 products offering multiple versions [3][4] - The differentiation in pricing is based on factors such as age, health status, income, and group insurance, with various products targeting specific demographics [3] Group 3: Coverage and Innovation - Over 80% of traditional 惠民保 products now include special drug coverage, with an average of 41 types of special drugs covered per product [5] - The focus on special drug coverage includes treatments for major diseases such as cancer and rare diseases, with participation from both domestic and international pharmaceutical companies [5] - The introduction of special drug directories and policies is expected to enhance the market acceptance of commercial health insurance, benefiting the 惠民保 market [5]